Last reviewed · How we verify
Continue with triple therapy
Triple therapy typically combines three complementary pharmacological agents to achieve synergistic therapeutic effects.
At a glance
| Generic name | Continue with triple therapy |
|---|---|
| Sponsor | Hospitales Universitarios Virgen del Rocío |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Without specification of which three agents comprise this regimen, the mechanism cannot be precisely defined. Triple therapy regimens vary widely depending on the therapeutic area and clinical context—for example, in cardiovascular disease it may combine agents targeting different pathways, while in infectious disease it may use multiple antimicrobial agents with different mechanisms. The specific combination determines the overall therapeutic action.
Approved indications
Common side effects
Key clinical trials
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (NA)
- Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients (PHASE2)
- Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer (NA)
- rTMS for Depression in Young Adults With Autism (NA)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
- A Study of Tetrathiomolybdate (TM) Plus Capecitabine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |